Safety in surgery: the checklist
Peter T. Scardino
p235 | doi:10.1038/nrurol.2009.76
Table of contents
May 2009 Vol 6 No 5
Editorial
Research Highlights
Prostate Cancer: Does PSA screening do more harm than good? | PDF (123 KB)
p237 | doi:10.1038/nrurol.2009.63
Urinary Incontinence: Gel calms overactive bladders | PDF (100 KB)
p238 | doi:10.1038/nrurol.2009.61
Biomarkers: Circulating tumor cells in prostate cancer | PDF (67 KB)
p238 | doi:10.1038/nrurol.2009.62
Male circumcision: HSV-2 and HPV | PDF (89 KB)
p239 | doi:10.1038/nrurol.2009.59
Prostate Cancer: Amelioration of risk by omega-3 modified by COX-2 | PDF (83 KB)
p240 | doi:10.1038/nrurol.2009.66
In brief
Radiotherapy | Pain | Prostate Cancer | Pediatrics | PDF (51 KB)
p240 | doi:10.1038/nrurol.2009.73
Bladder Cancer: Intravesical MCC for bladder cancer | PDF (147 KB)
p241 | doi:10.1038/nrurol.2009.64
Sexual Dysfunction: Erectile problems in teenagers commonly miscategorized as psychogenic | PDF (65 KB)
p241 | doi:10.1038/nrurol.2009.65
Infertility and cancer | PDF (60 KB)
p242 | doi:10.1038/nrurol.2009.31
Pediatrics: Treating OAB in children | PDF (111 KB)
p242 | doi:10.1038/nrurol.2009.43
Bladder Cancer: Aspirin reduces bladder cancer recurrence | PDF (110 KB)
p243 | doi:10.1038/nrurol.2009.58
In brief
Male factor infertility | Surgery | Sexual dysfunction | Clinical trials | PDF (52 KB)
p243 | doi:10.1038/nrurol.2009.72
Quality of life: Cancer survivors more likely to face unemployment | PDF (64 KB)
p244 | doi:10.1038/nrurol.2009.37
Prostate Cancer: Sarcosine indicates metastatic potential | PDF (217 KB)
p244 | doi:10.1038/nrurol.2009.60
News and Views
Surgery: Can checklists improve surgical outcomes?
John D. Birkmeyer & David C. Miller
p245 | doi:10.1038/nrurol.2009.57
In the quest to reduce the incidences of morbidity and mortality associated with surgery, a number of initiatives are being explored. Could a simple checklist provide an effective means of improving surgical outcome?
Urinary incontinence: Can weight loss treat urinary incontinence in obese women?
Christina Aye, Natalia Price & Simon R. Jackson
p247 | doi:10.1038/nrurol.2009.74
New research confirms that weight loss is an effective first-line intervention for overweight or obese women with urinary incontinence. Such patients should be encouraged to lose weight, but must also be given access to a full range of treatment options.
Prostate cancer: Thalidomide for prostate cancer: is there progress?
Eleni Efstathiou & Christopher J. Logothetis
p248 | doi:10.1038/nrurol.2009.68
Upon its 'reinvention', thalidomide was quickly applied to 'microenvironment-dependent' diseases such as multiple myeloma, yet its role in the solid tumor spectrum has not been validated. A report into recurrent prostate cancer by Figg et al.1 shows that thalidomide can reduce time to PSA progression in patients treated with androgen deprivation therapy.
Prostate cancer: Local control and radiotherapy matter in prostate cancer
Seth A. Rosenthal
p250 | doi:10.1038/nrurol.2009.56
In a study published in The Lancet, long-term androgen suppression (AS) combined with radiotherapy, compared with AS alone, improved outcomes in patients with locally advanced but nonmetastatic prostate cancer. The combined therapy significantly reduced prostate-cancer-specific deaths at 10 years from 23.9% to 11.9% (P <0.001), and improved overall survival.
Prostate cancer: Cardiovascular mortality and androgen deprivation
Shehzad Basaria
p252 | doi:10.1038/nrurol.2009.75
Every treatment has unintended adverse effects, and androgen deprivation therapy (ADT) for prostate cancer is no exception. A flurry of reports has implicated ADT in increasing cardiovascular risk and mortality. In this regard, the 2009 study by Efstathiou and colleagues is a notable exception.
Reviews
The use of PCA3 in the diagnosis of prostate cancer
Daphne Hessels & Jack A. Schalken
p255 | doi:10.1038/nrurol.2009.40
The discovery that prostate cancer gene 3 (PCA3) is overexpressed in malignant prostate cells has led to the development of a PCA3 urine test for prostate cancer. In this Review, the authors discuss the molecular marker PCA3 and its application in the diagnosis of prostate cancer and use as a prognostic indicator in men with prostate cancer.
Evaluation and management of priapism: 2009 update
Yun-Ching Huang, Ahmed M. Harraz, Alan W. Shindel & Tom F. Lue
p262 | doi:10.1038/nrurol.2009.50
Drawing on their own considerable experience, Huang and colleagues, from the University of California, San Francisco, review current therapies and emerging treatments for the management of priapism. Medical and surgical approaches to both the ischemic and nonischemic subtypes of this disorder are discussed.
Current management of emphysematous pyelonephritis
Alan R. Pontin & Richard D. Barnes
p272 | doi:10.1038/nrurol.2009.51
Emphysematous pyelonephritis is a severe, necrotizing, renal parenchymal infection that is characterized by the production of intraparenchymal gas. Predominantly affecting female diabetics, the presentation of this disorder has changed over the past 25 years. A more conservative approach to treatment is now recommended.
Glutathione S-transferases in kidney and urinary bladder tumors
Tatjana Simic, Ana Savic-Radojevic, Marija Pljesa-Ercegovac, Marija Matic & Jasmina Mimic-Oka
p281 | doi:10.1038/nrurol.2009.49
Glutathione S-transferases protect cells from toxic electrophilic compounds, including potential carcinogens, by catalyzing their conjugation to glutathione. These enzymes are found in both kidney and urothelial tissue. In this Review, Simic and colleagues discuss the relationships between enzyme polymorphism, altered expression, susceptibility to kidney and bladder tumors, and resistance to chemotherapy.
